How do patients report generic tigecycline's side effects vs name brand?

Short answer: There isn’t a difference in how you report side effects for generic tigecycline versus the brand-name (Tygacil). Both are the same active drug, and regulators collect adverse events for the product regardless of brand or generic status.

How to report adverse effects (US and general guidance)
- Primary option: FDA MedWatch
- Online: fda.gov/medwatch/report.htm
- Phone: 1-800-FDA-1088
- Mail/Fax: Complete the 3500 form and submit by mail or fax (instructions on the MedWatch site)
- Also you can report to the drug’s manufacturer (the company that makes the product you were given). They have their own safety reporting channels.
- Information to include when you report:
- The exact product name you took (brand name or “tigecycline” generic), and the manufacturer if known
- The lot number and expiry date if you have them
- Dose, route, start date and stop date
- A clear description of the adverse event and timing relative to dosing
- Other medicines or supplements you were taking
- Your age, sex, and any underlying conditions
- What happened as a result (medical care sought, change in therapy, outcome)

If you’re outside the US
- Europe/UK: EudraVigilance or your national regulator; patients can also report through their healthcare provider or the manufacturer.
- Canada: Health Canada’s adverse reaction reporting program.
- In general: Most regulators have a patient-friendly online form or contact number; you can also ask your clinician or pharmacist for help.

What to watch for
- Report serious or unusual symptoms promptly (seek urgent care if you have trouble breathing, swelling of face/tongue/throat, severe rash, severe jaundice, or other life-threatening signs).
- Common side effects of tigecycline include nausea, vomiting, diarrhea, and abdominal pain; serious adverse events should be reported, especially if they’re new, persistent, or worsening.

If you tell me your country, I can give you the exact steps and links for that regulator. Do you want US-specific guidance, or from another country?